Humanin / HNG – Mitochondrial-Derived Peptide

Humanin is a mitochondrial-derived peptide studied for cellular protection and metabolic biology. HNG is a modified analog of native humanin, and the two should not be considered interchangeable.

By

Peptide Dosing Library
Research & Education

Last reviewed

November 2026

2

Related Peptide Forms

3

Reported Research Contexts

20 mg

Example Calculation Amount

3

Key Evidence Limitations
Research reference for native humanin and its modified analog HNG

Humanin / HNG

Leave blank if this page contains no affiliate links. If affiliate links are added, disclose the relationship clearly.

OVERVIEW

Understanding Humanin / HNG

Humanin is a mitochondrial-derived peptide discussed in cellular protection and metabolic research. HNG is a modified analog with a distinct identity and should not be treated as identical to native humanin.

Peptide Name

Humanin / HNG

Peptide Origin

Mitochondrial-derived peptide

Primary Research Focus

Cellular protection and metabolic biology

Related Form

HNG is a modified analog of native humanin.

Research Models

Animal studies and observational human research

Evidence Context

Animal findings and associations with circulating humanin levels do not establish a beneficial human injection regimen.

Native Humanin vs HNG

HNG is a modified analog, not interchangeable with native humanin. Research findings should be interpreted according to the exact peptide form studied.

REPORTED RESEARCH SCHEDULES

Reported Research and Community Patterns

The source describes mouse HNG experiments and broad community-reported subcutaneous patterns. Animal study exposures are not human dosing recommendations, and community reports do not establish a validated human regimen.

SC example

Per administration

Frequency

Daily total

Reported cycle

Mouse Cardiac Study

4 mg/kg
Twice weekly
Not specified in source
14-month cardiac study

Mouse Metabolic Study

2.5 mg/kg
Twice daily
Not specified in source
Three days

Community-Reported SC Patterns

Milligram-range amounts; exact amount not specified
Daily to three times weekly
Not specified in source
Community-reported cycles of 4, 6–8 or 12 weeks

Mouse Cardiac Study

Per administration

4 mg/kg

Frequency

Twice weekly

Daily total

Not specified in source

Reported cycle

14-month cardiac study

Mouse Metabolic Study

Per administration

2.5 mg/kg

Frequency

Twice daily

Daily total

Not specified in source

Reported cycle

Three days

Community-Reported SC Patterns

Per administration

Milligram-range amounts; exact amount not specified

Frequency

Daily to three times weekly

Daily total

Not specified in source

Reported cycle

Community-reported cycles of 4, 6–8 or 12 weeks
Mouse HNG examples are intraperitoneal (IP) research exposures. Community examples are subcutaneous (SC) reports. These routes and contexts are not interchangeable.

Animal and Community Data Only

No beneficial human injection regimen is established by the source. Animal findings and community-reported schedules should not be interpreted as validated human treatment protocols.

SAFETY

Safety Considerations

Humanin and HNG remain exploratory research subjects. The source does not identify a controlled human safety dataset for exogenous humanin, and findings involving native humanin should not automatically be applied to HNG.

Important Safety and Evidence Limitations

Important Cautions

STORAGE & HANDLING

Storage and Research Monitoring

Storage

The source suggests keeping the product cold and protected from light.

Product Stability

Community-reported storage windows do not establish validated stability for human-use products.

Monitoring Considerations

Metabolic markers are discussed as exploratory research considerations.

Peptide Identity

Confirm whether research concerns native humanin or the modified HNG analog, as the two are not interchangeable.

CONCENTRATION WORKSHEET

Example Concentration Calculation

The source provides one independently recomputed mathematical concentration example. It is not a preparation or administration guide.

Amount (mg)

Final volume (mL)

Concentration (mg/mL)

Per 1 U (mcg)

Per 10 U (mcg)

20

2
10
100
1000

Amount (mg)

20

Final volume (mL)

2

Concentration (mg/mL)

10

Per 1 U (mcg)

100

Per 10 U (mcg)

1000

Amount (mg)

Final volume (mL)

Concentration (mg/mL)

Per 1 U (mcg)

Per 10 U (mcg)

U refers to a U-100 volume marking, where 1 U = 0.01 mL. These calculations are mathematical examples only, not mixing or administration instructions.

CLINICAL EVIDENCE

What Does the Research Show?

Human observational research has examined circulating humanin levels across different age groups and families with exceptional longevity. These associations do not establish that humanin injection improves health or treats disease.

01

Observational Plasma Research

Observational plasma studies have examined circulating humanin levels in human populations.

02

Age-Related Research

Observational plasma studies have examined circulating humanin levels in human populations.

03

No Established Injection Benefit

Endogenous humanin levels and stress responses do not establish a deficiency or prove that injection provides a clinical benefit.

REGULATORY INFORMATION

Regulatory and Research Limitations

Experimental Research Status

Animal findings and observational human associations do not establish an effective or safe human injection regimen. The source does not provide controlled human safety evidence for exogenous humanin.
This page is for educational and research reference only. It is not medical advice or a recommendation to use Humanin or HNG.